Atea Pharmaceuticals to report Q1 2026 financial results and business update on May 12.

Atea Pharmaceuticals announced it will hold a live conference call on May 12, 2026, to report its financial results for the first quarter ended March 31, 2026, and provide a business update. The company is a late-stage biopharmaceutical firm focused on developing oral antiviral therapies for serious viral diseases, including treatments for HCV and HEV. Investors can access the call via webcast or phone, with an archive available afterward. This update is important as Atea advances its antiviral drug pipeline, including Phase 3 trials and upcoming Phase 1 studies.